Lymphoma Clinical Trials in Philadelphia

Showing 341-360 of 701 trials

FDG-PET/CT Imaging as Early Predictor of DP

NCT02476734

In this study the investigators would like to describe FDG-PET/CT responses in patients who are receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects will undergo two FDG-PET/CTs. One performed within 6 weeks of CART-19 infusion and a repeat scan at about 1 month after infusion.

Lymphoma

Abramson Cancer Center at Penn Medicine9 participantsStarted Aug 2014

Philadelphia, Pennsylvania, United States

TERMINATEDPhase 2< 1 mile

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.

Lymphoma

Eastern Cooperative Oncology Group26 participantsStarted Aug 2007

Stanford, California, United States • Gainesville, Florida, United States • Jacksonville, Florida, United States +65 more locations

FDG-PET/CT Imaging as Early Predictor of DP

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Lymphoma Trials in Other Cities

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Maintenance Lenalidomide in Lymphoma

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Safety Study of SEA-CD40 in Cancer Patients

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Other Conditions in Philadelphia